Hey R 10
Just to be accurate, FYI there are expected to be 39 milestones over a period of 18 months
We should also note, that some milestones are duplicates, in the case of IHL-675A for example, the Data Readout from the Phase 1 Study is equal to 3 milestones one for each of the three indications - Inflammation, IBD & Rheumatoid Arthritis.
I am sure there will be some other Anouncemts to make up for any perceived shortfall such as;
>> Intentions/strategy/re-action to Australian TGA down-scheduling Psilocybin from Schedule 9 to 8.
>> Reverse "over liquid" ASX to resolve the "lack of liquidity" on the Nasdaq.
Quote from Joel "volumes on Nasdaq are currently less than on the ASX, we potentially foresee a time whereby this situation is reversed"
https://stocknessmonster.com/announcements/ihl.asx-3A608385/>> Manufacturing Update from Eurofins re manufacture and test chewable products to alleviate nicotine and opioid addiction.
>> Update on the PSI-GAD Patent Filing & IP Strategy/Methodology moving forward for PSI treatment/s?
>> Psychedelics - VR agreement/licensing arrangement/extension with Monash?
>> Manufacturing update from Curia on the inhaled device for IHL-216A
https://stocknessmonster.com/announcements/ihl.asx-3A598294/>> Bob Clarke update later in the year maybe??
Click the image to enlarge
Good luck
@Recruiter10
